Suchergebnisse - "Usmani, Saad Z"

PubPharm (37)

1

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma : TAURUS Chart Review Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Gordan, L. | Tan, C. | Vescio, R. | +12

2

Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma : Results From MajesTEC-1

enthalten in: Targeted oncology | 2023

von Miao, X. | Wu, L. | Lin, S. | +24

3

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) : A Randomized, Open-Label, Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Dimopoulos, M. | Oriol, A. | Nahi, H. | +19

4

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab : part 3 of the open-label, multicenter, phase 1b PAVO study

enthalten in: Leukemia & lymphoma | 2023

von Nahi, H. | Usmani, S. | Mateos, M. | +10

5

Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma : A multi-institutional experience

enthalten in: American journal of hematology | 2022

von Mohan, M. | Becnel, M. | Shah, U. | +29

6

Prognostic value of minimal residual disease negativity in myeloma : combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

enthalten in: Blood | 2022

von Cavo, M. | San-Miguel, J. | Usmani, S. | +24

CommentIn: Blood. 2022 Feb 10;139(6):799-802. - PMID 35142848

7

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

enthalten in: Blood | 2022

von San-Miguel, J. | Avet-Loiseau, H. | Paiva, B. | +24

CommentIn: Blood. 2022 Jan 27;139(4):469-471. - PMID 35084473

8

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR) : updated outcomes from a randomised, multicentre, open-label, phase 3 study

enthalten in: The Lancet. Oncology | 2022

von Usmani, S. | Quach, H. | Mateos, M. | +15

CommentIn: Lancet Oncol. 2022 Mar;23(3):e97. - PMID 35240098

9

Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma

enthalten in: Leukemia | 2021

von Usmani, S. | Karanes, C. | Bensinger, W. | +11

10

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA) : overall survival results from a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Facon, T. | Kumar, S. | Plesner, T. | +26